{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:17:13Z","timestamp":1777396633735,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1124\/dmd.123.001382","type":"journal-article","created":{"date-parts":[[2023,7,31]],"date-time":"2023-07-31T21:05:32Z","timestamp":1690837532000},"page":"1372-1380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4"],"prefix":"10.1016","volume":"51","author":[{"given":"Luc R.A.","family":"Roug\u00e9e","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasi","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trent L.","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001382_bib1","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/0003-2697(87)90261-2","article-title":"A fluorometric assay for quantitating phenol sulfotransferase activities in homogenates of cells and tissues","volume":"163","author":"Arand","year":"1987","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.123.001382_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2019.105409","article-title":"Reference intervals of nine steroid hormones over the life-span analyzed by LC-MS\/MS: Effect of age, gender, puberty, and oral contraceptives","volume":"193","author":"Bae","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1124\/dmd.123.001382_bib3","doi-asserted-by":"crossref","first-page":"14143","DOI":"10.1021\/bi051689t","article-title":"Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study","volume":"44","author":"Cameron","year":"2005","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib4","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1517\/17425250802500028","article-title":"Allosteric P450 mechanisms: multiple binding sites, multiple conformers or both?","volume":"4","author":"Davydov","year":"2008","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001382_bib5","doi-asserted-by":"crossref","first-page":"6797","DOI":"10.1074\/jbc.M111.325654","article-title":"Peripheral ligand-binding site in cytochrome P450 3A4 located with fluorescence resonance energy transfer (FRET)","volume":"287","author":"Davydov","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001382_bib6","doi-asserted-by":"crossref","first-page":"7066","DOI":"10.1074\/jbc.M609589200","article-title":"Cooperativity in cytochrome P450 3A4: linkages in substrate binding, spin state, uncoupling, and product formation","volume":"282","author":"Denisov","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001382_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.pharmthera.2009.05.011","article-title":"Cooperative properties of cytochromes P450","volume":"124","author":"Denisov","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001382_bib8","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.biochem.5b00079","article-title":"Mechanism of drug-drug interactions mediated by human cytochrome P450 CYP3A4 monomer","volume":"54","author":"Denisov","year":"2015","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib9","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1021\/acs.biochem.1c00161","article-title":"Midazolam as a Probe for Drug-Drug Interactions Mediated by CYP3A4: Homotropic Allosteric Mechanism of Site-Specific Hydroxylation","volume":"60","author":"Denisov","year":"2021","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib10","doi-asserted-by":"crossref","first-page":"853","DOI":"10.3390\/biom12060853","article-title":"Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4","volume":"12","author":"Denisov","year":"2022","journal-title":"Biomolecules"},{"key":"10.1124\/dmd.123.001382_bib11","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1021\/acs.biochem.8b01268","article-title":"Allosteric Interactions in Human Cytochrome P450 CYP3A4: The Role of Phenylalanine 213","volume":"58","author":"Denisov","year":"2019","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib12","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.bioconjchem.9b00248","article-title":"A Covalently Attached Progesterone Molecule Outcompetes the Binding of Free Progesterone at an Allosteric Site of Cytochrome P450 3A4","volume":"30","author":"Ducharme","year":"2019","journal-title":"Bioconjug Chem"},{"key":"10.1124\/dmd.123.001382_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1124\/dmd.121.000356","volume":"49","author":"Eng","year":"2020","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib14","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1124\/dmd.108.026252","article-title":"Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction","volume":"37","author":"Fahmi","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib16","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1074\/jbc.M110.182055","article-title":"Analysis of heterotropic cooperativity in cytochrome P450 3A4 using \u03b1-naphthoflavone and testosterone","volume":"286","author":"Frank","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1124\/dmd.123.001382_bib17","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.123.001382_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1124\/dmd.109.026716","article-title":"The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America","volume":"37","author":"Grimm","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1124\/dmd.108.021279","article-title":"Comparative analysis of CYP3A heteroactivation by steroid hormones and flavonoids in different in vitro systems and potential in vivo implications","volume":"36","author":"Henshall","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib20","doi-asserted-by":"crossref","first-page":"E2188","DOI":"10.1210\/jc.2014-1913","article-title":"Intra-tissue steroid profiling indicates differential progesterone and testosterone metabolism in the endometrium and endometriosis lesions","volume":"99","author":"Huhtinen","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/dmd.123.001382_bib21","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00216-008-2244-0","article-title":"Substrate binding to cytochromes P450","volume":"392","author":"Isin","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1124\/dmd.123.001382_bib22","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/tx500203s","article-title":"Role of protein-protein interactions in cytochrome P450-mediated drug metabolism and toxicity","volume":"27","author":"Kandel","year":"2014","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.123.001382_bib24","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s11095-012-0724-6","article-title":"Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction","volume":"29","author":"Kenny","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.123.001382_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0026-895X(24)12112-8","article-title":"Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation","volume":"61","author":"Khan","year":"2002","journal-title":"Mol Pharmacol"},{"key":"10.1124\/dmd.123.001382_bib26","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1124\/dmd.110.036400","article-title":"Prediction of CYP3A-mediated drug-drug interactions using human hepatocytes suspended in human plasma","volume":"39","author":"Mao","year":"2011","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib27","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1007\/s11095-016-1865-9","article-title":"Evaluation of Time Dependent Inhibition Assays for Marketed Oncology Drugs: Comparison of Human Hepatocytes and Liver Microsomes in the Presence and Absence of Human Plasma","volume":"33","author":"Mao","year":"2016","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.123.001382_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224081","article-title":"Rapid and structure-specific cellular uptake of selected steroids","volume":"14","author":"McManus","year":"2019","journal-title":"PLoS One"},{"key":"10.1124\/dmd.123.001382_bib29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-62703-758-7_5","article-title":"Irreversible enzyme inhibition kinetics and drug-drug interactions","volume":"1113","author":"Mohutsky","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1124\/dmd.123.001382_bib30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/dmd.30.5.534","article-title":"Effects of endogenous steroids on CYP3A4-mediated drug metabolism by human liver microsomes","volume":"30","author":"Nakamura","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/dmd.31.4.432","article-title":"CYP3A4 and CYP3A7-mediated carbamazepine 10,11-epoxidation are activated by differential endogenous steroids","volume":"31","author":"Nakamura","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib32","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3109\/00498258209038944","article-title":"Cytochrome P-450 metabolic-intermediate complex formation and induction by macrolide antibiotics; a new class of agents","volume":"12","author":"Pershing","year":"1982","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.123.001382_bib34","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1021\/acs.bioconjchem.6b00604","article-title":"Allosteric Activation of Cytochrome P450 3A4 via Progesterone Bioconjugation","volume":"28","author":"Polic","year":"2017","journal-title":"Bioconjug Chem"},{"key":"10.1124\/dmd.123.001382_bib35","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.abb.2018.06.014","article-title":"Steroid bioconjugation to a CYP3A4 allosteric site and its effect on substrate binding and coupling efficiency","volume":"653","author":"Polic","year":"2018","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.123.001382_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/acs.biochem.9b01001","article-title":"Dynamics and Location of the Allosteric Midazolam Site in Cytochrome P4503A4 in Lipid Nanodiscs","volume":"59","author":"Redhair","year":"2020","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/17425255.2015.1013095","article-title":"Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling","volume":"11","author":"Riley","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001382_bib38","doi-asserted-by":"crossref","first-page":"10804","DOI":"10.1021\/bi200924t","article-title":"The structural basis for homotropic and heterotropic cooperativity of midazolam metabolism by human cytochrome P450 3A4","volume":"50","author":"Roberts","year":"2011","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1073\/pnas.1616198114","article-title":"Structural basis for regiospecific midazolam oxidation by human cytochrome P450 3A4","volume":"114","author":"Sevrioukova","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/dmd.123.001382_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/0076-6879(95)49038-8","article-title":"Mechanism-based enzyme inactivators","volume":"249","author":"Silverman","year":"1995","journal-title":"Methods Enzymol"},{"key":"10.1124\/dmd.123.001382_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083898","article-title":"A large-scale allosteric transition in cytochrome P450 3A4 revealed by luminescence resonance energy transfer (LRET)","volume":"8","author":"Sineva","year":"2013","journal-title":"PLoS One"},{"key":"10.1124\/dmd.123.001382_bib42","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1021\/bi962359z","article-title":"Cooperativity in oxidations catalyzed by cytochrome P450 3A4","volume":"36","author":"Ueng","year":"1997","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.123.001382_bib43","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001382_bib44","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/dmd.32.2.259","article-title":"Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites","volume":"32","author":"Wang","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1126\/science.1099736","article-title":"Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone","volume":"305","author":"Williams","year":"2004","journal-title":"Science"},{"key":"10.1124\/dmd.123.001382_bib46","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1124\/dmd.108.025494","article-title":"Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator","volume":"37","author":"Xu","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001382_bib47","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624010675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001382","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T09:05:15Z","timestamp":1739955915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624010675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":45,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0090955624010675"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001382","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Heterotropic Allosteric Modulation on the Time-Dependent Inhibition of Cytochrome P450 3A4","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}